Leniolisib
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Leniolisib, sold under the brand name Joenja, is an anti-cancer medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor that is taken by mouth. The most common side effects include headache, sinusitis, and atopic dermatitis. Leniolisib was approved for medical use in the United States in March 2023, in the United Kingdom in September 2024, and in the European Union in May 2026. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration considers it to be a first-in-class medication. In 2025 NICE approved it for use in the British NHS.
Leniolisib, sold under the brand name Joenja, is an anti-cancer medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor that is taken by mouth. The most common side effects include headache, sinusitis, and atopic dermatitis. Leniolisib was approved for medical use in the United States in March 2023, in the United Kingdom in September 2024, and in the European Union in May 2026. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration considers it to be a first-in-class medication. In 2025 NICE approved it for use in the British NHS.
Mechanism of action
Leniolisib is a selective phosphoinositide 3-kinase inhibitor (PI3Kδ inhibitor), which means it blocks a form of the protein called phosphoinositide 3-kinase delta (PI3Kδ) that is overactive in activated PI3K delta syndrome. By inhibiting PI3Kδ, leniolisib helps normalize immune function as measured by a significant increase in number of immune response generating B cells and reduction in size of lymph nodes.
Adverse effects
The most common encountered adverse effects were headache, sinusitis, and atopic dermatitis.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378612635 under CC BY-SA 4.0; modifications have been made.